Qurin Diagnostics

Executive Summary

Qurin Diagnostics is a Netherlands-based biotech startup founded in 2020, dedicated to revolutionizing early cancer detection through non-invasive urine-based diagnostics. The company's lead product is a urine test for early bladder cancer detection, designed to improve diagnostic precision and patient compliance compared to invasive methods like cystoscopy. By leveraging a proprietary platform, Qurin aims to enhance test usability and accuracy, potentially enabling earlier intervention and better outcomes. The company is privately held with no disclosed funding or revenue, indicating an early development stage. Its focus on bladder cancer—a common and costly disease—positions it in a sizable market, but success hinges on clinical validation and regulatory clearance.

Upcoming Catalysts (preview)

• TBDInitial clinical study results for bladder cancer urine test60% success
• TBDPartnership with urology clinics or diagnostic labs50% success
• TBDRegulatory submission or CE marking in Europe40% success